Independent pathology review and biomarker interpretation for biotech and pharma programs where data quality and scoring accuracy drive development decisions.
Expert evaluation with findings, interpretation, and recommendations
IHC/IF analysis with clinical context
Technical evaluation of staining quality and protocol performance
Strategic assessment of biomarker or diagnostic program
Discussion of findings and implementation guidance
Rush turnaround available for urgent cases.
Prevents incorrect program decisions and wasted clinical spend
Identifies assay problems that invalidate results before they impact development
Eliminates variability that creates data quality issues and regulatory concerns
Ensures biomarker strategies support development goals and regulatory requirements
Identifies pathology data issues that don't meet submission requirements early
This is an advisory and consulting service. PathologyEdge does not certify, accredit, or approve laboratories. We do not operate as a clinical laboratory or provide regulatory approval services.
Review reports are intended to support internal decision-making and operational consistency. Our assessments are based on industry best practices and operational experience, structured to support program decisions.